Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec Deal Uses GSK Model; Partnerships To Double Pipeline By 2010

Executive Summary

Biogen and Idec are applying the GlaxoSmithKline model to the biotech world with their $6.8 bil. merger agreement

You may also be interested in...



The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire

Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.

Biogen Idec Highlights Manufacturing Capacity To Attract Partnerships

Biogen Idec plans to focus on licensing deals rather than mergers to grow its pipeline going forward, Executive VP-Business Development Mark Wiggins said during the company's analyst day Nov. 30

Biogen Idec Highlights Manufacturing Capacity To Attract Partnerships

Biogen Idec plans to focus on licensing deals rather than mergers to grow its pipeline going forward, Executive VP-Business Development Mark Wiggins said during the company's analyst day Nov. 30

Related Content

Latest News
UsernamePublicRestriction

Register

PS042027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel